U.S. markets close in 6 hours 26 minutes

Evogene Ltd. (EVGN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0286-0.0114 (-0.56%)
As of 09:30AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close2.0400
Bid1.9200 x 1000
Ask2.0500 x 1200
Day's Range2.0100 - 2.0286
52 Week Range1.7300 - 10.2400
Avg. Volume294,892
Market Cap83.506M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.7380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EVGN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evogene Ltd.
    Analyst Report: Quest Diagnostics IncorporatedQuest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of nearly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
    Fair Value
    Economic Moat
    14 hours agoMorningstar
View more
  • PR Newswire

    Hiscox EU Pan-European Transformation Goes Live in Germany with Sapiens Solutions in the Cloud

    Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the financial services industry, announced today that international specialist insurer Hiscox EU has gone live in Germany with Sapiens IDITSuite for Property & Casualty and Sapiens Intelligence, implemented in the cloud. Sapiens' flexible core platform and managed services provides Hiscox with operational efficiency, scalability, sustained profitability and enables the insurer to a

  • PR Newswire

    Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program

    Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported today positive results from pre-clinical studies in its IBD program. In these studies, Biomica tested its optimized drug candidate BMC333, which consists of four live bacterial strains derived from Biomica's drug candidates BMC321 and BMC322, which had been previously tested as well. Treatment with these drug candidates demonstr

  • PR Newswire

    Evogene Reports Third Quarter 2021 Financial Results

    Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first nine months and the third quarter of 2021, ended September 30, 2021.